Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Children’S Healthcare Of Atlanta Inc. is managing 1 pending office action in the Medical Devices & Mechanical Engineering technology area. This case is being reviewed by PHILIP EARL STIMPERT, who is the busiest examiner for the portfolio. The activity is confined to a distinct art unit, indicating a specialized focus for their medical technology interests. With only a distinct examiner and art unit involved, the prosecution strategy can be highly targeted.
The 1 pending office action represents the entirety of the company's current active portfolio. Because PHILIP EARL STIMPERT is the only examiner handling their work, the relationship with this individual is critical for their patent goals. The concentration in a distinct art unit allows the legal team to focus on the specific trends and rules of that section. Successfully navigating this pending office action will be the key to the company's immediate success in the Medical Devices & Mechanical Engineering sector. Practitioners should monitor the examiner's specific preferences to optimize the outcome of this filing.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BURKHART, MICHAEL D | 1 | 62.3% | +11.7% |
| STEIN, LEAH ELIZABETH | 1 | 100.0% | +0.0% |
| BUNKER, AMY M | 1 | 29.1% | +45.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18271364 | Interleukin-37, Chimeric Antigen Receptors, Nucleic Acids, and Vectors Encoding the Same and Uses in Cancer Therapies | STEIN, LEAH ELIZABETH | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17919481 | Immune Cell Redirecting Compositions and Therapeutic Uses Thereof | BUNKER, AMY M | 30d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17919481 | Immune Cell Redirecting Compositions and Therapeutic Uses Thereof | BUNKER, AMY M | 30d |
| 18654622 | GENETICALLY ENGINEERED DRUG RESISTANT T CELLS AND METHODS OF USING THE SAME | BURKHART, MICHAEL D | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18654622 | GENETICALLY ENGINEERED DRUG RESISTANT T CELLS AND METHODS OF USING THE SAME | BURKHART, MICHAEL D | — | §103§112DP | Non-Final OA | — | Pending | May 03, 2024 |
| 18271364 | Interleukin-37, Chimeric Antigen Receptors, Nucleic Acids, and Vectors Encoding the Same and Uses in Cancer Therapies | STEIN, LEAH ELIZABETH | 1641 | §103§112DP | Final Rejection | — | Pending | Jul 07, 2023 |
| 17919481 | Immune Cell Redirecting Compositions and Therapeutic Uses Thereof | BUNKER, AMY M | 1684 | §103 | Final Rejection | 30d | Pending | Oct 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial